HEALTH● LOWAug 10 · Aug 10, 2026, 4:59 PM
Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September
Seeking Alpha Tech
Tonix Pharmaceuticals has outlined plans for its TNX-4800 Phase II clinical trial involving approximately 3,300 participants, while also planning to scale its TONMYA sales force to about 150 representatives by September. This indicates key operational and research developments for the company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH39m agoEBOLA: Genomics links Nigeria’s case to Kenya index case – PateVanguard NigeriaHEALTH55m agoHow is Kerala planning to prevent child deaths linked to malnutrition and neglect? ExplainedThe HinduHEALTH1h agoModerna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trialnebraska.tv · United StatesHEALTH1h agoModerna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trialbakersfieldnow.com · United States